
Sign up to save your podcasts
Or


This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.
By Moira Gunn4.1
2929 ratings
This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on conventional therapies like steroids.

21,978 Listeners

43,923 Listeners

32,054 Listeners

30,726 Listeners

43,628 Listeners

707 Listeners

6,416 Listeners

30,193 Listeners

123 Listeners

321 Listeners

10,018 Listeners

34 Listeners

20 Listeners

51 Listeners

146 Listeners